Why is Lincoln Pharma. falling/rising?

As of 29-Aug, Lincoln Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 537.25, which reflects a decrease of 7.6 points or 1.39%. The stock has underperformed its sector by 1.42% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has seen a return of -2.92%, while its performance over the last month shows a decline of 1.30%. Despite a rise in delivery volume by 30.41% against the 5-day average, the overall sentiment remains negative, with a significant drop in profits of 11.8% over the past year contributing to the stock's poor performance, which has resulted in a year-to-date decline of 32.08%.
In the broader market context, Lincoln Pharmaceuticals has underperformed compared to the Sensex, which has shown a positive return of 2.14% year-to-date. The stock's long-term growth prospects appear weak, with net sales and operating profit growing at rates of only 9.87% and 7.84%, respectively, over the last five years. Additionally, the company's low debt-to-equity ratio and attractive valuation metrics are overshadowed by its flat results in June and a low return on capital employed (ROCE) of 16.54%. The lack of investment from domestic mutual funds, which hold 0% of the company, further indicates a lack of confidence in the stock's potential, contributing to its recent decline.